Kevin Martin · Prescription Drug Costs
The Same Pill, the Same Factory, the Same Company. Three Times the Price Because You Live Here.
Americans pay about 278% of what other developed countries pay for the same drugs. Negotiation started on ten of them in January 2026. Kevin Martin on why ten is not the finish line.
I want to start with the number, because the number is the whole argument.
A 2024 RAND study found that U.S. drug prices, before rebates, averaged about 278% of prices in 33 other developed countries in 2022. For brand-name drugs it was roughly 422%. Same medication. Often the same manufacturer, sometimes the same plant. The difference is which country you happen to be standing in when you hand over the card.
I am a numbers person by trade, and I have looked at a lot of pricing over the years. When the same good sells for four times as much in one market, that is not a manufacturing cost. That is a negotiating position.
Something did change in January
Give credit where it is due, because it is real.
Under the Inflation Reduction Act, Medicare was given authority to negotiate prices on a limited set of high-cost drugs. The first negotiated prices took effect on January 1, 2026, covering ten medications. The negotiated prices came in at a minimum of 38% off the 2023 list price, and CMS estimated that, had those prices been in effect in 2023, beneficiaries would have saved roughly $1.5 billion out of pocket and Medicare about $6 billion.
That is a genuine win, and I am not going to pretend otherwise just because I am a Republican and it passed under a Democratic administration. If it worked, it worked.
There is also a second track in the works. CMS has proposed two models, called GLOBE and GUARD, tying what drugmakers owe Medicare on certain drugs to what other countries pay, benchmarked against a basket of 19 nations. They were proposed in December 2025 and, as of this writing, have not been finalized. The general idea, sometimes called most-favored-nation pricing, is that the United States should not pay more than the best price a comparable country gets.
I think that idea is basically right, and I would say so no matter who proposed it.
So what is left to argue about
Ten drugs.
There are thousands of prescription medications on the market. The negotiation program covers ten so far. Fifteen more take effect in January 2027, and another fifteen are being negotiated now for 2028. Meanwhile the person picking up a prescription that is not on the list is paying exactly what they were paying before.
So the honest framing is not "Washington fixed drug prices." It is that Washington proved the mechanism works on ten of them and then moved slowly.
There is also a real objection worth taking seriously, which I will state fairly because I think people can handle it. Drug companies argue that American prices fund the research that produces new drugs, and that if we pay what Europe pays, we get what Europe develops. That is not a stupid argument. It deserves an actual answer rather than a slogan.
My answer is that it is an argument for figuring out how research gets funded, not an argument for letting one country carry the whole load through its sick people. A retired machinist in Douglasville is not a research grant.
What Congress actually controls
Almost all of it, and this is worth being precise about because people assume drug pricing is something that just happens.
Congress wrote the law that let Medicare negotiate at all, and Congress wrote the limit on how many drugs. Congress sets the patent and exclusivity rules that determine how long a drug stays protected from competition. Congress decides the rules for generics and biosimilars. Congress can require price transparency, and Congress decides how much of this applies outside Medicare.
Every one of those is a decision, not a condition.
What needs to change
Expand the negotiation list, faster. The mechanism exists and the first round worked. The argument for a slow phase-in was that we did not know what would happen. Now we have data. Speed it up.
Take most-favored-nation pricing seriously. If a drug company will sell to Germany at a given price, that price is by definition profitable. There is no version of the argument where the profitable price becomes unprofitable at the American border.
Fix the patent games. A lot of what keeps prices high is not the original patent. It is the practice of stacking minor modifications to extend protection long past the point where competitors should have entered. That is a rule Congress wrote.
Then measure it. Not "prices are lower." How much lower, on which drugs, for whom, compared to what. If a policy cannot produce that number, it is not a policy.
Why this one is personal for a lot of people here
The thing about drug prices is that nobody experiences it as a policy debate. They experience it standing at a counter, being told a number, and doing math in their head about whether to fill it this month.
You should not have to be sophisticated about federal pricing policy to afford your own prescription. That is the government's job to get right, and for a long time it did not even try.
It has started. It is not close to finished.
Sources
- KFF — Understanding the Negotiated Drug Prices for Medicare
- Medicare Rights Center — Negotiated Prices Take Effect for Ten Drugs in 2026
- NIH / PMC — Assessment of IPAY 2027 maximum fair prices against most-favored-nation reference countries
- RAND via NIH / PMC — International Prescription Drug Price Comparisons: Estimates Using 2022 Data
- CMS — Selected Drugs and Negotiated Prices
- Federal Register — Global Benchmark for Efficient Drug Pricing (GLOBE) Model, Proposed Rule